Silence Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLNCF research report →
About the company
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the company's approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, meticulously crafted to precisely target specific disease-causing genes, predominantly within the liver.
- CEO
- Iain Gladstone Ross
- IPO
- 2012
- Employees
- 116
- HQ
- London, GB
Price Chart
- Market Cap
- $212.56M
- P/E
- -2.41
- P/S
- 532.57
- P/B
- 9.93
- EV/EBITDA
- -6.21
- Div Yield
- 0.00%
- Gross Margin
- 66.43%
- Op Margin
- -9396.64%
- Net Margin
- -9243.05%
- ROE
- -121.71%
- ROIC
- -82.66%
- Revenue
- $559.00K · -98.71%
- Net Income
- $-88,612,000 · -95.57%
- EPS
- $-0.63 · -90.91%
- Op Income
- $-82,290,000
- FCF YoY
- -14.95%
- 52W High
- $2.63
- 52W Low
- $1.06
- 50D MA
- $1.77
- 200D MA
- $1.76
- Beta
- 1.38
- Avg Volume
- 454
Get TickerSpark's AI analysis on SLNCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SLNCF coverage
Recent articles, reports, and earnings notes.
No research on SLNCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLNCF report →Similar companies
Peers in the same neighborhood.